TITAN PHARMACEUTICALS INC — Director's Dealing 2016

Feb 2, 2016

SEC Form 4/A — Form 4/A

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2015-12-14

Reporting Person: BHONSLE SUNIL (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-14	Option to Purchase Common Stock	$5.10	A	90900	Acquired	2025-12-14	Common Stock (90900)	Direct

Footnotes

F1: The options vest in 24 equal monthly installments commencing on the grant date.